3P Biotechnologies, Inc.
Publicly observedProspect, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Prospect | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | 3P Biotechnologies, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | HSCNW2K7VN97 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: Trans Spinal Delivery of Targeted Exosomal Formulation of Curcuminoids to Treat AD
USD 506,434.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant25 Sept 2024Publicly observed
NIH SBIR/STTR award: Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD
USD 6,500.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.